Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy

Mutation Research - Reviews in Mutation Research

Volumn 658, Issue 1-2, 2008, Pages 55-67

  Stiborová, Marie ^a   Frei, Eva ^b   Arlt, Volker M ^c   Schmeiser, Heinz H ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aristolochic acid; Aristolochic acid nephropathy; Balkan endemic nephropathy; DNA adducts; Reductive activation

Indexed keywords

ARISTOLOCHIC ACID; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; PROSTAGLANDIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

BIOTRANSFORMATION; CARCINOGENESIS; CHEMICAL STRUCTURE; DNA ADDUCT; DRUG DETOXIFICATION; ENZYME ACTIVATION; HUMAN; INTERSTITIAL NEPHRITIS; LIVER MICROSOME; METABOLIC ACTIVATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; ARISTOLOCHIC ACIDS; BALKAN NEPHROPATHY; BIOTRANSFORMATION; CARCINOGENS; CYTOCHROME P-450 CYP1A2; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; RISK FACTORS;

EID: 38649109829     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2007.07.003     Document Type: Review

References (114)

1. International Agency for Research on Cancer. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 82 (2002)
2. Kumar V., Ponam D., Prasad A.K., and Parmar V.S. Naturally occurring aristolactams, aristolochic acids and diaxoapophines and their biological activities. Nat. Prod. Rep. 20 (2003) 565-583
3. Rücker G., and Chung B.S. Aristolochic acids from Aristolochia manshuriensis. Planta Med. 27 (1975) 68-71
4. Hahn G. Die Osterluzei - Aristolochia clematitis - eine alte Medizinal-Pflanze. DR Med. 8 (1979) 41-43
5. Priestap H.A. Minor aristolochic acids from Aristolochia argentina and mass spectral analysis of aristolochic acids. Phytochemistry 26 (1987) 519-529
6. Möse J.R. Weitere Untersuchungen über die Wirkung der Aristolochiasäure. Drug Res. 16 (1966) 118-122
7. Möse J.R. Weitere Studien über Aristolochiasäure. Drug Res. 24 (1974) 151-153
8. Kluthe R., Vogt A., and Batsford S. Doppelblindstudie zur Beeinflussung der Phagocytosefähigkeit von Granulocyten durch Aristolochiasäure. Drug Res. 32 (1982) 443-445
9. Mengs U., Lang W., and Poch J.A. The carcinogenic action of aristolochic acid in rats. Arch. Toxicol. 107 (1982) 107-119
10. Mengs U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Arch. Toxicol. 52 (1983) 209-220
11. Robisch G., Schimmer O., and Göggelmann W. Aristolochic acid is a direct mutagen in Salmonella typhimurium. Mutat. Res. 105 (1982) 201-204
12. Abel G., and Schimmer O. Induction of structural chromosome abberations and sister chromatid exchanges in human lymphocytes in-vitro by aristolochic acid. Hum. Genet. 64 (1983) 131-133
13. Frei H., Würgler F.E., Juon H., Hall C.B., and Graf U. Aristolochic acid is mutagenic and recombinogenic in Drosophila genotoxicity tests. Arch. Toxicol. 56 (1985) 158-166
14. Pezutto J.M., Swanson S.M., Woongchon M., Che C., Cordell G.A., and Fong H.H.S. Evaluation of the mutagenic and cytostatic potential of aristolochic acid (3,4-methylenedioxy-8-methoxy-10-nitrophenanthrene-1-carboxylic acid) and several of its derivatives. Mutat. Res. 206 (1988) 447-454
15. Kevekordes S., Burghaus C.M., Spielberger J., Mersch-Sundermann V., Schmeiser H.H., Arlt V.M., and Dunkelberg H. SOS induction of selected naturally occuring substances in Escherichia coli (SOS chromotest). Mutat. Res. 445 (1999) 81-91
16. Kevekordes S., Spielberger J., Burghaus C.M., Birkenkamp P., Zietz B., Paufler P., Diez M., Bolten C., and Dunkelberg H. Micronucleus formation in human lymphocytes and in the metabolically competent human hepatoma cell line Hep-G2: results with 15 naturally occurring substances. Anticancer Res. 21 (2001) 461-470
17. Mengs U. Acute toxicity of aristolochic acid in rodents. Arch. Toxicol. 59 (1987) 328-331
18. Mengs U. Tumor induction in mice following exposure to aristolochic acid. Arch. Toxicol. 61 (1988) 504-505
19. Mengs U., and Stotzem C.D. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch. Toxicol. 87 (1993) 307-311
20. In: Reynolds K.F.F. (Ed). Martindale, The Extra Pharmacopeia (1986), Pharmaceutical Press, London 130
21. Houghton P.J., and Ogutveren M. Aristolochic acids and aristolactams from Aristolochia auricularia. Phytochemistry 30 (1991) 253-254
22. 2 from Vipera russelli with aristolochic acid. Toxicon 25 (1987) 939-946
23. Vanherweghem J.L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., Richard C., Valdervelde D., Verbeelen D., Vanhaelen-Fastre B., and Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341 (1993) 387-391
24. Vanhaelen M., Vanhaelen-Fastre B., But P., and Vanherweghem J.L. Identification of aristolochic acid in Chinese herbs. Lancet 343 (1994) 174
25. Vanhaelen M., Cuykens J.J., Vandenberg P.H., Bouman K.P., and Hagens Y. Valvular heart disease and Chinese-herbs nephropathy. Lancet 351 (1998) 991
26. Martinez M.C., Nortier J., Vereerstaeten P., and Vanherweghem J.L. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol. Dial. Transplant. 17 (2002) 408-412
27. Cosyns J.-P. Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Saf. 26 (2003) 33-48
28. Arlt V.M., Stiborova M., and Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002) 265-277
29. Gillerot G., Jadoul M., Arlt V.M., van Ypersele de Strihou C., Schmeiser H.H., But P.H.H., Bieler C.A., and Cosyns J.-P. Aristolochic acid nephropathy in a Chinese patient: time to abandon the term "Chinese herbs nephropathy"?. Am. J. Kidney Dis. 38 (2001) E26
30. Solez K., Daugirdes J., Gregory M.C., Frohnert P.P., Blownik D.M., Iha V., and Cosyns J.-P. Is "Chinese Herbs Nephropathy" a prejudical term?. Am. J. Kidney Dis. 38 (2001) 1141-1142
31. Cosyns J.-P., Jadoul M., Squifflet J.P., Wese F.X., and van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33 (1999) 1011-1017
32. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., and Vanherweghen J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (2000) 1686-1692
33. Lord G.M., Cook T., Arlt V.M., Schmeiser H.H., Williams G., and Pusey C.D. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358 (2001) 1515-1516
34. Arlt V.M., Alunni-Perret V., Quatrehomme G., Ohayon P., Albano L., Gaid H., Michiels J.F., Meyrier A., Cassuto E., Wiessler M., Schmeiser H.H., and Cosyns J.-P. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int. J. Cancer 111 (2004) 977-980
35. Lo S.H., Wong K.S., Arlt V.M., Phillips D.H., Lai C.K., Poon W.T., Chan C.K., Mo K.L., Chan K.W., and Chan A. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am. J. Kidney Dis. 45 (2005) 407-410
36. Ivic M. Etiology of endemic nephropathy. Lijec. Vjesn. 91 (1969) 1273-1281
37. Tatu C.A., Oren W.H., Finkelman R.B., and Feder G.L. The etiology of Balkan endemic nephropathy: still more questions than answers. Environ. Health Perspect. 106 (1998) 689-700
38. Arlt V.M., Ferluga D., Stiborova M., Pfohl-Leszkowicz A., Vukelic M., Ceovic S., Schmeiser H.H., and Cosyns J.-P. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer?. Int. J. Cancer 101 (2002) 500-502
39. Pfohl-Leszkowicz A., Petkova-Bocharova T., Chernozemsky I.N., and Castegnaro M. Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins. Food Addit. Contam. 19 (2002) 282-302
40. Stiborová M., Patočka J., Frei E., and Schmeiser H.H. Biochemistry and toxicological aspects of etiology of Balkan endemic nephropathy. Chem. Listy 99 (2005) 782-788 (in Czech)
41. Stefanovic V., Toncheva D., Atanasova S., and Polenakovic M. Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am. J. Nephrol. 26 (2006) 1-11
42. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R., Goodenough A.K., Rieger R., Vukelic M., and Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12129-12134
43. Hranjec T., Kovac A., Kos J., Mao W., Chen J.J., Grollman A.P., and Jelakovic B. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat. Med. J. 46 (2005) 116-125
44. Schmeiser H.H., Schoepe K.-B., and Wiessler M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9 (1988) 297-303
45. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11 (1990) 1627-1633
46. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15 (1994) 1187-1192
47. Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele de Strihou C., and Cosyns J.-P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56 (1996) 2025-2028
48. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18 (1997) 1063-1067
49. Stiborová M., Frei E., Breuer A., Bieler C.A., and Schmeiser H.H. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp. Toxicol. Pathol. 51 (1999) 421-427
50. Arlt V.M., Pfohl-Leszkowicz A., Cosyns J.-P., and Schmeiser H.H. Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat. Res. 494 (2001) 143-150
51. Pfau W., Schmeiser H.H., and Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11 (1990) 313-319
52. 6-Adenyl arylation of DNA by aristolochic acid II and a synthetic model for the putative proximate carcinogen. Chem. Res. Toxicol. 4 (1991) 581-586
53. 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci. Publ. 124 (1993) 167-171
54. Cosyns J.-P., Goebbels R.-M., Liberton V., Schmeiser H.H., Bieler C.A., and Bernard A.M. Chinese herbs nephropathy-associated slimming regimen induces tumors in the forestomach but no interstitial nephropathy in rats. Arch. Toxicol. 72 (1998) 738-743
55. 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug. Metab. Dispos. 34 (2006) 1122-1127
56. Schmeiser H.H., Janssen W., Lyons J., Scherf H.R., Pfau W., Buchmann A., Bartram C.R., and Wiessler M. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50 (1990) 5464-5469
57. Arlt V.M., Wiessler M., and Schmeiser H.H. Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. Carcinogenesis 21 (2000) 235-242
58. Arlt V.M., Schmeiser H.H., and Pfeifer G.P. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22 (2001) 133-140
59. Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., and Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43 (2004) e11-e17
60. Liu Z., Hergenhahn M., Schmeiser H.H., Wogan G.N., Hong A., and Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2963-2968
61. Feldmeyer N., Schmeiser H.H., Muehlbauer K.R., Belharazem D., Knyazev Y., Nedelko T., and Hollstein M. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat. Res. 608 (2006) 163-168
62. Arlt V.M., Stiborová M., vom Brocke J., Simões M.L., Lord G.M., Nortier J.L., Hollstein M., Phillips D.H., and Schmeiser H.H. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis (2007) (Epub ahead of print)
63. Mix D.B., Guinaudeau H., and Shamma M. The aristolochic acids and aristolactams. J. Nat. Prod. 45 (1982) 657-666
64. Krumbiegel G., Hallensleben J., Mennicke W.H., and Rittmann N. Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17 (1987) 981-991
65. Chan W., Cu L., Xu G., and Cai Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20 (2006) 1755-1760
66. Chan W., Luo H.-B., Zheng Y., Cheng Y.-K., and Cai Z. Investigation of the metabolism and reductive activation of carcinogenic aristolochic acid in rats. Drug Metab. Dispos. 35 (2007) 866-874
67. Schmeiser H.H., Pool B.L., and Wiessler M. Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7 (1986) 59-63
68. Maier P., Schawalder H., and Weibel B. Low oxygen tension as found in tissues in vivo, alters the mutagenic activity of aristolochic acid I and II. Environ. Mol. Mutagen. 10 (1987) 275-284
69. Schmeiser H.H., Pool B.L., and Wiessler M. Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett. 23 (1984) 97-98
70. Stiborová M., Frei E., Schmeiser H.H., and Wiessler M. Cytochrome P-450 and peroxidase oxidize detoxication products of carcinogeneic aristolochic acids (aristolactams) to reactive metabolites binding to DNA in vitro. Collect. Czech. Chem. Commun. 60 (1995) 2189-2199
71. Eling T.E., Thompson D.C., Foureman G.L., Curtis J.F., and Hughes M.F. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 1-45
72. Eling T.E., and Curtis J.F. Xenobiotic metabolism by prostaglandin H synthase. Pharm. Ther. 53 (1992) 261-273
73. Smith G., Stanley L.A., Sim E., Strange R.C., and Wolf R. Metabolic polymorphism and cancer susceptibility. Cancer Surv. 25 (1995) 27-65
74. Toncheva D., Dimitrov T., and Stojanova S. Etiology of Balkan endemic nephropathy: a multifactorial disease?. Eur. J. Epidemiol. 14 (1998) 389-394
75. Atanasova S., von Ahsen N., Dimitrov T., Amstrong V., Oellerich M., and Toncheva D. MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with balkan endemic nephropathy compared to healthy controls. Nephron Exp. Nephrol. 96 (2004) 7-13
76. Toncheva D.I., von Ahsen N., Atanasova S.Y., Dimitrov T.G., Amstrong V.M., and Oellerich M. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Blakan endemic nephropathy. J. Nephrol. 17 (2004) 384-389
77. Atanasova S.Y., von Ahsen N., Toncheva D.I., Dimitrov T.G., Oellerich M., and Amstrong V.M. Genetic polymorphism of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin. Biochem. 38 (2005) 223-228
78. Toncheva D. Genetic studies in BEN and associated urothelial cancers. Coll. Antropol. 30 Suppl. 1 (2006) 34
79. 32P-post-labeling: evidence for reductive activation by peroxidases. Carcinogenesis 18 (1997) 1055-1062
80. 32P-postlabeling analysis of DNA adduct formation. Mutat. Res. 493 (2001) 153-164
81. Stiborová M., Frei E., Wiessler M., and Schmeiser H.H. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochrome P450 1A1 and 1A2. Chem. Res. Toxicol. 14 (2001) 1128-1137
82. Stiborová M., Frei E., Hájek M., and Schmeiser H.H. Carcinogenic and nephrotoxic aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen. Physiol. Biophys. 20 (2001) 375-392
83. Stiborová M., Frei E., Sopko B., Wiessler M., and Schmeiser H.H. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23 (2002) 617-625
84. Stiborová M., Frei E., Sopko B., Sopková K., Marková V., Laňková M., Kumstýřová T., Wiessler M., and Schmeiser H.H. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24 (2003) 1695-1703
85. Stiborová M., Sopko B., Hodek P., Frei E., Schmeiser H.H., and Hudecek J. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett. 229 (2005) 193-204
86. Stiborová M., Frei E., Hodek P., Wiessler M., and Schmeiser H.H. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113 (2005) 189-197
87. Stiborová M., Martínek V., Rýdlová H., Hodek P., and Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 62 (2002) 5678-5684
88. Rendic S., and DiCarlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997) 413-480
89. Stiborová M., Frei E., and Schmeiser H.H. Metabolic activation of aristolochic acid. Coll. Antropol. 30 Suppl. 1 (2006) 25
90. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., Devanoboyina U.S., Nangiu C.A., and Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 29-42
91. Glatt H., Boeing H., Engelke C.E.H., Ma L., Kuhlow A., Pabel U., Pomplun D., Teubner W., and Meinl W. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. 482 (2001) 27-40
92. Meinl W., Pabel U., Osterloh-Quitroz H., Hengstler J.G., and Glatt H. Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int. J. Cancer 118 (2006) 1090-1097
93. Henderson C.J., Otto D.M.E., Carrie D., Magnuson M.A., McLaren A.W., Rosewell I., and Wolf C.R. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278 (2003) 13480-13486
94. Henderson C.J., Otto D.M., McLaren A.W., Carrie D., and Wolf C.R. Knockout mice in xenobiotic metabolism. Drug Metab. Rev. 35 (2003) 385-392
95. Perera F.P. Environment and cancer: who are susceptible?. Science 278 (1997) 1068-1073
96. Landi M.T., Sinha R., Lang N.P., and Kadlubar F.F. Human cytochrome P4501A2. In: Vineis P., Malats N., Lang M., d'Errico A., Caporaso N., Cuzick J., and Boffetta P. (Eds). Metabolic Polymorphisms and Susceptibility to Cancer (1999), International Agency for Research on Cancer, IARC Sci. Publ., Lyon 173-195 No. 148
97. Guengerich F.P., Parikh A., Turesky R.I., and Josephy P.D. Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat. Res. 428 (1999) 115-124
98. Schuetz E.G., Schmid W., Schurt G., Brimer C., Yasuda K., Kamataki T., Borheim L., Myles K., and Cole T.J. The glucocorticoid receptor is essential for drug or steroid induction of CYP3A or P-450 reductase in mouse liver. Drug Metab. Dispos. 28 (2000) 268-278
99. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., and Siegel D. NAD(P)H:quinone oxidoreductase (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem.-Biol. Interact. 129 (2000) 77-97
100. Ernster L. DT-diaphorase: a historical review. Chem. Scr. 27A (1987) 1-13
101. Riley R.J., and Workman P. DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol. 43 (1992) 1657-1669
102. Long II D.J., and Jaiswal A.K. NRH:Quinone oxidoreductase2 (NQO2). Chem. -Biol. Interact. 129 (2000) 99-112
103. Schulz W.A., Krummeck A., Rosinger I., Eickelman P., Neuhaus C., Ebert T., Schmitz-Drager B.J., and Sies H. Increased frequency of a null-allele for NAD(P)H-quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 7 (1997) 235-239
104. Chen H.W., Luni A., Seifried A., Wilkens L.R., and Le Marchand L. Association of the NAD(P)H-quinone oxidoreductase C-609-T polymorphism with a decreased lung-cancer risk. Cancer Res. 59 (1999) 3045-3048
105. Dhakshinamoorthy S., Long II D.J., and Jaiswal A.K. Antioxidant regulation of genes enconding enzymes that detoxify xenobiotics and carcinogens. Curr. Top. Cell. Regul. 36 (2000) 201-216
106. Joseph P., Jaiswal A.K., Stobbe C.C., and Chapman J.D. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 29 (1994) 351-355
107. Talalay P., and Prochaska H.J. Mechanism of induction of NAD(P)H:quinone reductase. Chem. Scr. 27A (1987) 61-66
108. Montano M.M., and Katzenellenbogen B.S. The quinone reductase gene-a unique receptor-regulated gene that is activated by antiestrogens. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2581-2586
109. Montano M.M., Jaiswal A.K., and Katzenellenbogen B.S. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. J. Biol. Chem. 273 (1998) 25443-25449
110. Nebert D.W., and Jones J.E. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int. J. Biochem. 3 (1989) 243-252
111. Stiborová M., Hájek M., Vošmiková H., Frei E., and Schmeiser H.H. Isolation of DT-diaphorase (NAD(P)H dehydrogenase (quinone)) from rat liver cytosol: identification of new enzyme substrates, carcinogenic aristolochic acids. Collect. Czech. Chem. Commun. 66 (2001) 959-972
112. Larson R.A., Wang Y., Banerjee M., Wiemels J., Hartford C., Beau M.M., and Smith M.T. Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukaemia. Blood 94 (1999) 803-807
113. Clairmont A., Sies H., Ramachandran S., Lear J.T., Smith A.G., Bowers B., Jones P.W., Fryer A.A., and Strange R.C. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 20 (1999) 1235-1240
114. Wiemels J., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. A lack of functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res. 59 (1999) 4095-4099